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Abstract Poor prognosis of lung adenocarcinoma is associ-
ated with early occurrence of distant metastases. This type of
non-small-cell lung carcinoma more frequently involves
EGFR gene abnormalities, which determine the efficacy of
EGFR tyrosine kinase inhibitor therapies (EGFR TKIs). It is
probable that genetic abnormalities present in primary tumor
will also be present in metastases. Unfortunately little is
known about the incidence of these mutations in the metasta-
ses and about the effectiveness of molecularly targeted therapy
in such patients. Formalin-fixed, paraffin-embedded tumor
tissue was prepared from 431 samples of primary adenocarci-
noma, 61 of adenocarcinoma central nervous system (CNS)
metastases and 8 of adenocarcinoma bone metastases. The
presence of exon 19 deletions was examined using the PCR
technique and amplified PCR product fragment length analy-
sis. The ASP-PCR technique was used to evaluate the L858R
substitutions in exon 21, and the results were analyzed using
ALF Express II sequencer. In the adenocarcinoma metastases
to bone obtained from 8 patients, deletions in exon 19 of the
EGFR gene were revealed in 3 smoking men and one non-
smoking woman, while L858R substitution in exon 21 was
found in one smoking woman and one man of unknown
smoking status. The incidence of EGFR gene mutations in
the bonemetastases was 75%, in the primary adenocarcinoma
- 12.8 %, and in the adenocarcinoma metastases to CNS -
14.75 %. Five patients with EGFR gene mutation revealed in
bone metastases were treated with EGFR TKIs; the majority
of them had a satisfactory response to therapy.
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FFPE Formalin-fixed, paraffin-embedded
NSCLC non-small-cell lung cancer
PCR polymerase chain reaction
PFS progression free survival
Introduction
Lung adenocarcinoma is currently the most common type of
non-small-cell lung cancer (NSCLC) diagnosed in the pop-
ulations of developed countries (more than 40 % of all
NSCLC cases). Changes in habits related to smoking took
place in these countries, which is especially apparent in
female population. Due to the spread of smoking addiction
among women (usually light cigarettes) and the ever-
increasing number of ex-smokers, lung adenocarcinoma,
which occurs more frequently in women (especially of Asian
origin), and the etiology of which is moderately associated
with the action of tobacco smoke carcinogens, has risen to
first place in terms of incidence, surpassing squamous cell
carcinoma (strongly associated with the action of tobacco
smoke carcinogens). Lung adenocarcinoma not associated
with smoking is characterized by different biology and mo-
lecular profile than smoking-related NSCLC. EGFR (epider-
mal growth factor receptor) gene mutations and ALK (ana-
plastic lymphoma kinase) gene rearrangements are often
revealed in adenocarcinoma cells in non-smoking patients;
this has been used for qualifying patients for EGFR tyrosine
kinase inhibitor therapy (erlotinib, gefitinib) and ALK inhib-
itor therapy (crizotinib). Moreover, mutations in KRAS,
PIK3CA, BRAF, DDR2, MEK, and other genes are more
frequently revealed in adenocarcinoma patients than in pa-
tients with other types of NSCLC [1–4].
The molecular profile of lung adenocarcinoma and its
moderate association with cigarette smoking influence the
biology of this neoplasm. Adenocarcinoma (AC), more often
than other types of NSCLC, originates from the epithelium
of peripheral and small bronchi, or even pulmonary alveoli
(e.g. adenocarcinoma of alveolar septa with lepidic growth
pattern, previously bronchioloalveolar carcinoma associated
with EGFR gene mutations) and often produces metastases
to the lymph nodes and distant metastases to the central
nervous system, liver, adrenal glands, and bones. Because
of this, less than 15 % of adenocarcinoma patients can be
treated surgically. The remaining patients who have good
performance status, but suffer from locally advanced and
advanced adenocarcinoma, can receive systemic treatment
in the form of chemoradiotherapy, chemotherapy or molec-
ularly targeted therapy [1, 2, 4, 5].
Clinical studies have demonstrated the high efficacy of
EGFR tyrosine kinase inhibitors (TKIs) in the 1st line of
treatment for patients with NSCLC with activating mutations
in the EGFR gene (most frequently with L858R substitution
in exon 21 or deletion in exon 19), resulting in the extension
of progression free survival (PFS) to 10 months in nearly
70 % of patients. Similar efficacy of EGFR TKIs was noted
in patients with EGFR mutations after the failure of standard
1st line chemotherapy. Unfortunately, only 10 % of adeno-
carcinoma patients of Caucasian origin are carriers of EGFR
gene mutations (this percentage amounts to over 40 %
among Asian patients). What is more, the majority of studies
concerned with EGFR gene mutations pertained to primary
lung adenocarcinoma. Less information is available on the
incidence of these mutations in metastatic adenocarcinoma
tumors and on the efficacy of EGFR TKIs therapy in such
cases. It is highly probable that genetic abnormalities present
in the cells of the primary tumor will also be present in the
metastases. This is why current molecular testing guidelines
admit the possibility of labeling the EGFR mutations in the
metastatic tumor if adequate material from the primary can-
cerous focus is not present. Nonetheless, taking into consid-
eration the heterogeneity of primary NSCLC tumors, one can-
not exclude the possibility of the occurrence of metastasis
consisting of a different clone of neoplastic cells that have no
EGFR gene mutations. It is also not known whether the pres-
ence of EGFR gene mutations favors the occurrence of metas-
tases, and whether it is related to their organ location [3–8].
Bone environment is considered to be poorly differentiated,
which could suggest resistance to foreign cell settlement.
Nevertheless, metastases to bone are revealed in 30–40 % of
NSCLC patients. As the NSCLC metastasizes to bone, nu-
merous and complicated mechanisms must be activated. Their
result is the movement of progenitor cancer cells from blood
vessels and marrow to skeletal tissue (changed osteolytically
by the activated osteoclasts), after which they achieve the
capacity for proliferation and clonal growth [4, 5, 9–12].
The skeleton is one of the most common locations where
the NSCLC metastases develop; their primary locations in-
clude the spine, pelvis, ribs, femur, and ilium. The extensive
vascularization of these bone types is probably significant
here, as it exposes the bones to more contact with cancer cells
traveling through the vascular lumen. Significantly worse
prognosis was noted in patients with appendicular bone me-
tastases in comparison to patients with axial bone metastases
[7, 8, 10]. However, the etiology of the development of
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NSCLC metastases to bone has not been entirely explained,
and the international literature almost completely lacks analysis
of the status of the EGFR gene in NSCLC metastases to bone.
The research subject of the present study was the evalua-
tion of the incidence of EGFR activating mutations in lung
adenocarcinoma metastases to bone. We also analyzed the
incidence of these mutations in the primary lung adenocar-
cinoma and in adenocarcinoma metastases to the central
nervous system (CNS), as well as the efficacy of EGFR
TKI therapy in 5 patients with EGFR gene mutations re-
vealed in adenocarcinoma metastases to bone.
Material and Methods
Formalin-fixed, paraffin-embedded (FFPE) tumor tissue was
prepared from 431 samples of locally advanced or advanced
primary adenocarcinoma (AC), 61 samples of AC brain
metastases and 8 samples of AC bone metastases. Patients
characteristics of AC primary tumor and AC brain metasta-
ses are presented in Table 1. Detailed clinical data of the
patients with EGFR gene mutations examined in AC bone
metastases is shown in Table 2.
DNA was isolated from the FFPE tissue using a QIAmp
DNA FFPE Tissue Kit (Qiagen, Canada) according to the
manufacturer’s instructions. Quantitative and qualitative anal-
ysis of the isolatedDNAwas performed on Biophotometer Plus
(Eppendorf, Germany). The presence of exon 19 deletions was
examined using the PCR technique and amplified PCR product
fragment length analysis. In order to evaluate the L858R sub-
stitutions in exon 21, the ASP-PCR (allele-specific PCR) tech-
nique was used along with two pairs of PCR primers. PCR
primers were labeled with Cy5 fluorochrome. The results were
analyzed on an ALF Express II sequencer (Tables 2, 3 and 4).
To estimate the sensitivity of the applied techniques, the
serial dilutions of DNA from lung cancer cell lines NCI-
H1650 and NCI-H1975 with delE747-A750 and L858R
mutations into DNA isolated from healthy donors’ PBMCs
were performed to reach 100 % wild type and 50 %, 25 %,
20 %, 10 %, 5 %, 2 % and 1 % of mutant DNA by volume. It
was demonstrated that 10 % of mutated DNA diluted with
the control DNA (wild-type) was the sensitivity cut-off point
for PCR followed by fragment length analysis for delE746-
A750 in exon 19 while for ASP-PCR detection for L858R
mutation of EGFR it was 5 % of mutated-DNA diluted with
95 % wild-type DNA. Moreover the test was validated by
European Molecular Quality Network. Therefore we did not
apply direct sequencing as it is a low sensitivity method.
Statistical analysis employed a chi-square test to compare
the number of patients with and without EGFR mutation in
different subgroups.
The study was approved by the Ethical Committee of the
Medical University in Lublin (decision no. KE-0254/131/2011).
Results
Activating mutations in the EGFR gene occurred significantly
more frequently in adenocarcinoma bone metastases (75 %)
than in the primary lung adenocarcinoma (12.8 %, χ2=25.43,
p<0.00001) or in the adenocarcinoma metastasis to CNS
(14.75 %, χ2=15.09, p<0.0001). Mutations in the primary
lung adenocarcinoma and in its metastases to CNS were sig-
nificantly more common among women than among men
(respectively: χ2=9.17, p=0.0025 and χ2=4.03, p<0.05). Ac-
tivating mutations in the EGFR gene were revealed in both
women with adenocarcinoma metastases to bone. These muta-
tions were also revealed in the AC bone metastases in 4 men;
however, the presence of EGFRmutations was excluded in two
men in this material. It is noteworthy that the vast majority of
patients with EGFR gene mutations revealed in bone metasta-
ses were smokers. The median age of the patients with EGFR
gene mutations found in the primary tumor (63 years) was
insignificantly higher than the median age of patients with the
presence of this mutation revealed in the metastatic tumor to
CNS (50 years) or bones (59.5 years).
In the material obtained from primary lung adenocarcinoma
tumors and the material from AC bone metastases, deletions in
Table 1 Patients characteristic
Feature Primary adenocarcinoma Brain metastases
Age Median (mean±standard deviation) 63 (63±9 years) 59 (60±9 years)
Gender Female 121 17
Male 310 44
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exon 19 were slightly more common than L858R substitutions
in exon 21 of the EGFR gene. In the adenocarcinoma metasta-
ses to CNS, mutation in exon 21 was more common than
deletions in exon 19.
The presence of EGFRmutations in both bone metastases
and the primary lung tumor was confirmed only in patient
J.A. In the remaining patients, mutation was only revealed in
bone metastases. In these patients, the material from primary
tumors was not available for the analysis of mutations in the
EGFR gene.
Four patients with activating mutations in the EGFR gene,
which were revealed in adenocarcinoma bone metastases,
were treated with EGFR TKIs. Patient J.A. did not receive
this kind of treatment due to the presence of symptomatic
metastases in the CNS, while patient B.M., after receiving
the results concerning EGFR gene mutations, had poor per-
formance status (PS=3) and died shortly after.
Patient G.Z. received erlotinib as the third line of treat-
ment, after the failure of first line chemotherapy with cisplat-
in and vinorelbine, and second line monotherapy with the
use of docetaxel. The patient was qualified for erlotinib
treatment based on the high amplification of the EGFR gene
in 80 % of the cancer cells; mutation in exon 19 of the EGFR
gene was, in this case, revealed retrospectively. The result of
the erlotinib treatment was the complete remission of meta-
static lesions in the CNS, partial remission of diffuse lesions
in the lungs and liver metastases, and stabilization of bone
lesions. The disease was under control for 9 months, after
which rapid progression took place and the patient died after
10 months from the commencement of erlotinib therapy
[13]. Patient K.K., after the failure of first line chemotherapy
with cisplatin and vinorelbine, received second line therapy
with erlotinib. This enabled the achievement of partial remis-
sion of lesions in the lungs and stabilization of bone metasta-
ses, which has been sustained to this day (for 13 months).
Patient Z.Z. received first line gefitinib treatment and achieved
stabilization of bone and lung lesions, which has been
sustained to this day (4 months). Patient J.R. was qualified
for first line gefitinib treatment; however, after 2 months,
further progression of the disease was revealed in his case.
Discussion
Mutations in the tyrosine kinase domain of the EGFR gene
constitute independent predictive factors in EGFR TKI ther-
apy, determining the occurrence of therapy response in over
70 % of patients [1, 4, 6]. They are most often found in
Asians (30–50 %), women and non-smokers. Its incidence in
the Caucasian population of NSCLC patients does not ex-
ceed 10 % [14].
Y. Togashii et al. found that, in half of the patients with
EGFR gene mutations, distant metastases were also diag-
nosed (11 out of 22 patients with EGFR gene mutations).
Moreover, metastasis was diagnosed much less frequently in
the cases of lung adenocarcinoma with wild-type EGFR gene
(4 out of 33 patients with wild-type EGFR gene). What is
more, the majority of patients with diagnosed EGFR gene
Table 2 Clinical data of patients with lung adenocarcinoma metastases to the skeleton
Patient Gender Age Tobacco smoking status EGFR gene status Site of metastasis
J.A Woman 65 Non-smoker Deletion in exon 19 Femur
Z.Z Man 55 Smoker (45 pack-years) Deletion in exon 19 Spine, humerus
F.J Man 82 Smoker (180 pack-years) Wild-type Radial bone
G.Z Man 44 Smoker (15 pack-years) Deletion in exon 19 Ilium
J.R Man 60 Former smoker (15 pack-years) Deletion in exon 19 Numerous bone metastases
K.K Woman 74 Former smoker (pack-years - no data) Substitution in exon 21 Ribs and skull bones
D.T Man 53 No data Wild-type Skull bones
B.M Man 59 No data Substitution in exon 21 Rib bones
Table 3 The incidence of acti-
vating mutations of the EGFR
gene in primary tumors of lung
adenocarcinoma
Primary lung adenocarcinoma, n=431
EGFR gene mutations in primary lung adenocarcinoma tumors, n=55 (12.8 %)
Deletions in exon 19 n=32 (58.2 %) L858R substitution in exon 21 n=23 (41.8 %)
Women n=16 Women n=14
Men n=16 Men n=9
Age (median, mean±SD, years) 63, 62±10 Age (median, mean±SD, years) 63, 63±9
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mutation in distant NSCLC metastases smoked cigarettes
[15]. This research may suggest that the presence of the
mutation may be a factor conducive to the occurrence of
distant metastases in NSCLC patients.
Sun et al. assessed the status of the EGFR and KRAS
genes in a population of 80 NSCLC in whom material from
both the primary tumors and the lymph node metastases was
available. Mutations of the KRAS gene, which may cause a
more aggressive course of the disease and resistance to
EGFR TKIs treatment, were found in 7 samples of lymph
node metastases; only in one case was this mutation found in
the primary tumor as well. On the other hand, EGFR gene
mutations were found in 21 primary tumors and 26 lymph
node metastases; in all patients with mutations in the primary
tumors, their presence was also confirmed in the metastases.
This research does not confirm the relation between the
presence of EGFR mutations and the higher likelihood of
NSCLC metastases to the lymph nodes [7].
Few studies assessing the presence of EGFR mutations in
lung cancer metastases to CNS have been conducted in
Asian patients. Matsumoto et al. examined 21 tissue samples
from metastatic brain tumors found in 19 NSCLC patients
(68 % of whom were smokers). EGFR mutations were iden-
tified in 12 out of these 19 cases (63 %), including 10 short
in-frame deletions in exon 19 and two L858R substitutions in
exon 21. In all cases in which EGFRmutations were found in
the primary tumors, they were also present in the correspond-
ing brain metastases. It is postulated that, in Asian patients,
the frequency of EGFR mutations in metastatic brain tumors
of lung adenocarcinoma is higher than in primary tumors (c.
40 %) [16]. In the studies Caucasian population, the frequen-
cy of EGFR mutations in brain metastases of AC is only
slightly higher than in primary tumors (12,8 % vs. 14,8 %).
When it comes to the incidence of EGFR mutations in
bone metastases of adenocarcinoma, we are not aware of any
available reports on this subject. The incidence of this mu-
tation in our material is surprisingly high. On the one hand,
this may result from the pre-selection of patients for molec-
ular examination with regard to their qualification for EGFR
TKIs therapy, as well as from the very low number of studied
patients. On the other hand, it could be hypothesized that the
presence of EGFR mutations is conducive to the occurrence
of distant metastases to bone and, on the basis of the studies
mentioned above, also to other locations, including the brain.
What is more, this phenomenon may be to some degree
independent from the influence of tobacco smoke carcino-
gens. It is not, therefore, possible to exclude the theory that
the neoplastic progenitor cells settling in distant organs are
carriers of various genetic abnormalities, which may not be
found in the cells of the primary tumor [7, 8, 10, 12].
In the only study concerning the EGFR status in bone
metastases of NSCLC, Badalian et al. studied the expression
of the EGF receptor in 11 metastatic bone tumors and pri-
mary tumors coming from the same patients. The authors
demonstrated that in 45.5 % of patients, high EGFR expres-
sion occurred in both tumor types. In turn, EGFR expression
was higher in bone metastases than in the primary focus of
the neoplasm in 36.4 % of patients; in 18.2 % of patients, the
opposite relation was observed. Moreover, the status of the
KRAS gene was assessed in the same tissue material. It was
established that the incidence of this mutation exceeded
27 % in both the primary tumors and metastases. However,
not in all patients were these mutations found in both the
studied samples at the same time [11].
The assessment of the genetic profiles of primary and met-
astatic tumors serves the purpose of choosing the best therapy,
which could extend the progression-free survival and improve
the quality of life of the patients in advanced stages of the
disease. Even though it is assumed that molecular diagnostics
should be performed for primary tumors, it is also acceptable to
examine the EGFR gene status in metastatic tumors. The meta-
analysis performed by Petrelli et al. indicates that EGFR TKIs
are indisputably effective in NSCLC patients with confirmed
activatingmutation in theEGFR gene, regardless of the stage of
the disease and the location of distant metastases (in numerous
clinical studies, patients with stage IV NSCLC were qualified
for EGFR TKI therapy) [4].
Sugiura et al. retrospectively selected 83 Asian patients with
bone metastases of lung adenocarcinoma, 52 of whom had good
performance status despite the advancement of the disease; 14
patients were qualified for gefitinib therapy and the remaining 38
for systemic treatment. It turned out that even without previous
diagnosis of EGFRmutation, the total survival time was longer
by 7 months on average in the group of patients receiving
Table 4 The incidence of acti-
vating mutations of the EGFR
gene in the material from lung
adenocarcinoma metastases to
CNS
Lung adenocarcinoma CNS metastases, n=61
EGFR gene mutations in lung adenocarcinoma brain metastases , n=9 (14.8 %)
Deletions in exon 19 n=3 (33.3 %) L858R substitution in exon 21 n=6 (66.7 %)
Women n=1 Women n=4
Men n=2 Men n=2
Age (median,mean±SD, years) 50, 56±14 Age (median,mean±SD, years) 59, 62±9
The incidence of EGFR-activating mutations in bone metastases 111
EGFR TKIs (17.6 months) in comparison to the group not
treated with gefitinib (10.8 months). Nevertheless, the authors
emphasize that the previous establishment of the EGFR gene
status would have enabled the precise selection of those
patients for whom the therapy would be most beneficial [8].
Furugaki et al. conducted an animal model analysis of the
mechanism behind the action of erlotinib in the treatment of
NSCLC bone metastases with the use of the NCI-H292 lung
cancer cell line (which exhibits high potential for bone
metastasis). They demonstrated that the use of molecularly
targeted therapy led to the suppression of EGF receptor-
dependent proliferation, a decrease in the production of
osteolytic factors and, the inhibition of osteolysis influencing
the RANKL/RANK signaling pathway in osteoclasts, de-
spite the wild status of the EGFR gene [17].
Conclusions
All these reports suggest that detailed assessment of the
EFGR gene status in the available AC bone metastasis ma-
terial is highly useful in qualifying patients for EGFR TKIs
therapy. The high percentage of patients in whom the muta-
tion was found in AC bone metastases suggests that the
presence of deletion in exon 19 or, less frequently, L858R
substitution in exon 21 of the EGFR gene may be conducive
to the development of metastasis. On the other hand, the
study group was very small and the status of the mutation
was assessed in the patients qualified for EGFR TKI treat-
ment (preliminary selection of patients). The patients with
EGFR gene mutations found in bone metastases of AC
benefited from EGFR TKIs therapy, which further confirms
the usefulness of such material in molecular diagnostics.
Open Access This article is distributed under the terms of the Creative
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